GlassScriptPhysician profile
Rhonda K Bray
NPI 1285623512
$1,200.35
in general payments reported to CMS, 2019-2025
12 companies · $464 in 2025
The $464 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.50 · 2021: $19.10 · 2022: $88.72 · 2023: $289 · 2024: $301 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $459.49 | 2021-2025 | Total30, Clareon, Precision7 |
| Tarsus Pharmaceuticals, INC. | $226.71 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $121.60 | 2025 | |
| Bausch & Lomb Americas INC. | $84.12 | 2024-2025 | Infuse, Miebo, Xiidra |
| Dompe US, INC. | $67.53 | 2024 | Oxervate |
| Lkc Technologies, INC. | $62.58 | 2024-2025 | |
| Genentech USA, INC. | $48.64 | 2022 | |
| Abbvie INC. | $33.75 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $33.61 | 2025 | |
| Biotissue Holdings INC. | $22.82 | 2025 | |
| Optovue, INC. | $22.26 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.